Tocilizumab in Extracranial Giant-Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Tocilizumab (TCZ) has demonstrated potential efficacy in managing large-vessel (LV) vasculitis such as giant-cell arteritis (GCA) and Takayasu arteritis (TAK). Despite the shared characteristics between the LV-GCA phenotype and TAK, there are differences between both entities that may affect therape...
Saved in:
| Main Authors: | Carmen Lasa-Teja, Javier Loricera, Diana Prieto-Peña, Fernando López-Gutiérrez, Pilar Bernabéu, María Mercedes Freire-González, Beatriz González-Alvarez, Roser Solans-Laqué, Mauricio Mínguez, Iván Ferraz-Amaro, Santos Castañeda, Ricardo Blanco, on behalf of the Tocilizumab in Large-Vessel Vasculitis Spanish Collaborative Group |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Sci |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2413-4155/7/1/12 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
by: G. M. Koilubaeva, et al.
Published: (2022-05-01) -
Anesthetic Management of Parturients with Takayasu’s Arteritis: A Series of Three Cases
by: Nilesh M. Solanki, et al.
Published: (2025-01-01) -
Difficulties in the Diagnosis and Management of Patients with Takayasu’s Arteritis: A Description of a 5-Year Clinical Follow-Up
by: A. V. Petrov, et al.
Published: (2023-10-01) -
The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)